Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

Exclusion Criteria

• •\<18 years of age
• •Pregnant or lactating female
• •Patient has islet cell neoplasms
• •Patient has known brain metastases
• •Patient has metastatic disease
• •Active secondary malignancies
• •Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• •Known infection with hepatitis B, hepatitis C, or cirrhosis
• •Major surgery or vascular device placement (excluding ports for IV medication/chemotherapy) within 2 weeks prior to Day 1 of treatment in study
• •Prior chemotherapy or radiation for pancreatic cancer
• •History of allergy or hypersensitivity to the study drugs
• •Patient is enrolled in any outside (outside Baylor University Medical Center or Texas Oncology) clinical protocol or investigational trial
• •Significant cardiac disease as defined as New York Heart Association (NYHA) classification III or IV, uncontrolled congestive heart failure (CHF), or prior myocardial infarction (MI) last 6-months
• •Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation which in the opinion of the investigator may place the patient at increased risk
• •Peripheral sensory neuropathy ≥ to grade 2 at baseline
• •Significant co-morbidities deemed by investigator as unsuitable for participation/enrollment
• •Study consent form not signed